Skip to main content

Table 5 Overview of treatment emergent adverse events (SAF, n = 24)

From: Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model - a clinical trial

 

Total

Untreated

2.8 mg dose

5.5 mg dose

11.0 mg dose

 

(N = 24)

(N = 24)

(N = 18)

(N = 19)

(N = 20)

 

N (%)a

n

N (%)a

n

N (%)a

n

N (%)a

n

N (%)a

n

All TEAEs

23

(95.8)

77

16

(66.7)

24

10

(55.6)

17

11

(57.9)

21

10

(50.0)

15

Severe

1

(4.2)

1

 

 

1

(5.3)

1

 

Possibly related

4

(16.7)

7

 

1

(5.6)

1

3

(15.8)

6

 

Related

2

(8.3)

2

 

 

1

(5.3)

1

1

(5.0)

1

  1. AE adverse event, N number of subjects, n number of events, SAF safety analysis set, TEAE treatment emergent adverse event
  2. aPercentages are based on the total number of subjects